Connect Biopharma Holdings (CNTB) Current Assets (2020 - 2026)

Connect Biopharma Holdings (CNTB) has reported Current Assets for 7 consecutive years, with $55.0 million the latest figure, recorded in Q1 2026.

• Quarterly Current Assets fell 37.3% year-over-year to $55.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.0 million (down 37.3% YoY) and the FY2025 annual result came in at $50.9 million, down 47.47% from the prior year.
• Current Assets advanced to $55.0 million in Q1 2026 per CNTB's latest filing, from $50.9 million in the prior quarter.
• Over the last five years, Current Assets for CNTB reached as high as $197.8 million in Q2 2022 and fell as low as $50.9 million in Q4 2025.
• A 5-year average of $105.3 million and a median of $97.0 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets dropped 16.12% — and 2025, when it sank 47.47%.
• Year by year, Current Assets stood at $152.5 million in 2022, then decreased by 19.66% to $122.6 million in 2023, then fell by 20.88% to $97.0 million in 2024, then plunged by 47.47% to $50.9 million in 2025, then gained by 8.03% to $55.0 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $55.0 million, $50.9 million, and $62.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.